Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 3/20 | 0.76 |
| ▸ | FOS | P01100 | 2/20 | 0.76 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.47 |
| ▸ | UGT1A3 | P35503 | 1/20 | 0.47 |
| ▸ | UGT1A8 | Q9HAW9 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968731 | 0.94 | JUN (0.70) | JUNFOSUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL4282160 | 0.93 | JUN (0.66) | JUNFOSUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL4276620 | 0.92 | JUN (0.81) | JUNFOSUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL4282700 | 0.90 | JUN (0.81) | JUNFOSUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL4277010 | 0.90 | JUN (0.61) | JUNFOSUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL2968375 | 0.89 | JUN (0.61) | JUNFOSUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL2960328 | 0.87 | JUN (0.59) | JUNFOSUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL1527292 | 0.87 | FOS (1.00) | JUNFOSLTB4RLTB4R2ELANE | |
| SCHEMBL31191805 | 0.87 | FOS (1.00) | JUNFOSLTB4RLTB4R2ELANE | |
| SCHEMBL4288990 | 0.86 | JUN (0.73) | JUNFOSUGT1A1UGT1A3UGT1A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | JUN 20/4885FOS 63/4885UGT1A1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.